Core Viewpoint - Zhuzhou Qianjin Pharmaceutical Co., Ltd. reported significant growth in core profit indicators for the fiscal year 2025, with a stable operating performance and positive responses to investor concerns regarding market value management, R&D pace, and new industrialization layout [1][2][3] Financial Performance - The company achieved total operating revenue of approximately 3.635 billion yuan, a slight increase of 0.13% year-on-year [2][7] - Operating profit reached about 440 million yuan, a substantial increase of 32.64% year-on-year [2][7] - Total profit was approximately 438 million yuan, up 30.73% year-on-year [2][7] - Net profit attributable to shareholders was around 288 million yuan, reflecting a year-on-year growth of 24.74% [2][7] - Basic earnings per share increased to 0.6414 yuan, a rise of 14.97% year-on-year [2][7] Asset and Equity Growth - As of the end of 2025, total assets were approximately 5.045 billion yuan, representing a growth of 10.71% from the beginning of the period [2][8] - Shareholder equity attributable to the company was about 3.030 billion yuan, a year-on-year increase of 23.06% [2][8] - The number of shares increased to approximately 492 million, up 16.09% from the previous year [2][8] Reasons for Performance Growth - The growth in performance was attributed to steady revenue growth from core industrial enterprises and improved profitability [3][9] - The acquisition of 28.92% of Hunan Qianjin Xiangjiang Pharmaceutical and 68% of Hunan Qianjin Xieli Pharmaceutical contributed positively to the financial results starting from October and November 2025 [3][9] Market Value Management - The company emphasized its commitment to market value management, maintaining a high dividend payout ratio since its listing to reward shareholders [3][9] R&D and Innovation - R&D innovation is a key focus, with plans to increase investment and optimize product layout, currently having nine innovative drugs in development [5][11] - The company is implementing a digital transformation strategy across its operations to enhance efficiency and reduce costs, utilizing AI technology in various operational aspects [5][11] Channel Operations - Qianjin Pharmacy operates approximately 1,800 stores, with significant growth in sales of flu-related medications driven by market demand [6][12]

Group 1 - The core viewpoint of the article highlights that Qianjin Pharmaceutical (600479) is implementing a digital transformation strategy across its entire value chain, aiming to reduce costs and improve efficiency [1] - The company's AI capabilities are being applied in various areas including research project initiation, production scheduling, procurement sourcing, decision-making for bulk medicinal materials, marketing knowledge assistance, and AI training [1] - The recent acquisition of minority shareholder rights in two companies is a significant step in executing the company's medium to long-term strategic plan, which is expected to enhance profitability and increase net profit attributable to the parent company [1] Group 2 - Qianjin Pharmacy currently operates approximately 1,800 stores, with a notable year-on-year increase in sales of influenza-related medications [1]